FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100041918> ?p ?o ?g. }

• W2100041918 endingPage "402" @default.
• W2100041918 startingPage "397" @default.
• W2100041918 abstract "Background An economic evaluation was performed analyzing direct medical costs in Canada for the treatment of perennial allergic rhinitis (PAR) with budesonide aqueous nasal spray and fluticasone propionate nasal spray. Three hundred fourteen patients with at least a 1-year history of PAR were randomized into a double-blind, parallel-group study of 6 weeks' duration. The treatments were daily doses of budesonide 256 μg, fluticasone propionate 200 μg, or placebo. Both active treatments produced significantly lower mean scores for overall nasal symptoms compared with placebo, and both were well tolerated. Budesonide was significantly more effective than fluticasone in reducing blocked nose. Method A retrospective cost-effectiveness analysis utilizing the clinical trial data was performed on the total costs of (1) budesonide-based and (2) fluticasone-based treatment strategies, including the relative importance of the drug costs in both strategies. Results The average treatment cost per patient in Canada over 12 months in the budesonide group was CAD 389.85 which was 23.3% lower than in the fluticasone group, which it was CAD 508.06, due to lower drug acquisition costs (for the year 1998). Conclusion Budesonide aqueous nasal spray was shown to be more cost-effective than fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. This result is valid in the province of Ontario, Canada and in many other settings with the same structure of relative prices. The result is mainly driven by a difference in drug cost. An economic evaluation was performed analyzing direct medical costs in Canada for the treatment of perennial allergic rhinitis (PAR) with budesonide aqueous nasal spray and fluticasone propionate nasal spray. Three hundred fourteen patients with at least a 1-year history of PAR were randomized into a double-blind, parallel-group study of 6 weeks' duration. The treatments were daily doses of budesonide 256 μg, fluticasone propionate 200 μg, or placebo. Both active treatments produced significantly lower mean scores for overall nasal symptoms compared with placebo, and both were well tolerated. Budesonide was significantly more effective than fluticasone in reducing blocked nose. A retrospective cost-effectiveness analysis utilizing the clinical trial data was performed on the total costs of (1) budesonide-based and (2) fluticasone-based treatment strategies, including the relative importance of the drug costs in both strategies. The average treatment cost per patient in Canada over 12 months in the budesonide group was CAD 389.85 which was 23.3% lower than in the fluticasone group, which it was CAD 508.06, due to lower drug acquisition costs (for the year 1998). Budesonide aqueous nasal spray was shown to be more cost-effective than fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. This result is valid in the province of Ontario, Canada and in many other settings with the same structure of relative prices. The result is mainly driven by a difference in drug cost." @default.
• W2100041918 created "2016-06-24" @default.
• W2100041918 creator A5012533144 @default.
• W2100041918 creator A5012765848 @default.
• W2100041918 creator A5053617733 @default.
• W2100041918 creator A5078537346 @default.
• W2100041918 date "2000-04-01" @default.
• W2100041918 modified "2023-10-12" @default.
• W2100041918 title "Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis" @default.
• W2100041918 cites W1968972903 @default.
• W2100041918 cites W1987137654 @default.
• W2100041918 cites W2018382314 @default.
• W2100041918 cites W2035457686 @default.
• W2100041918 cites W2068448073 @default.
• W2100041918 cites W2119539558 @default.
• W2100041918 doi "https://doi.org/10.1016/s1081-1206(10)62271-5" @default.
• W2100041918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10795647" @default.
• W2100041918 hasPublicationYear "2000" @default.
• W2100041918 type Work @default.
• W2100041918 sameAs 2100041918 @default.
• W2100041918 citedByCount "16" @default.
• W2100041918 countsByYear W21000419182016 @default.
• W2100041918 countsByYear W21000419182019 @default.
• W2100041918 crossrefType "journal-article" @default.
• W2100041918 hasAuthorship W2100041918A5012533144 @default.
• W2100041918 hasAuthorship W2100041918A5012765848 @default.
• W2100041918 hasAuthorship W2100041918A5053617733 @default.
• W2100041918 hasAuthorship W2100041918A5078537346 @default.
• W2100041918 hasConcept C126322002 @default.
• W2100041918 hasConcept C142724271 @default.
• W2100041918 hasConcept C204787440 @default.
• W2100041918 hasConcept C27081682 @default.
• W2100041918 hasConcept C2776136866 @default.
• W2100041918 hasConcept C2776804153 @default.
• W2100041918 hasConcept C2779028295 @default.
• W2100041918 hasConcept C2780973058 @default.
• W2100041918 hasConcept C2781212218 @default.
• W2100041918 hasConcept C42219234 @default.
• W2100041918 hasConcept C71924100 @default.
• W2100041918 hasConcept C85663871 @default.
• W2100041918 hasConcept C98274493 @default.
• W2100041918 hasConceptScore W2100041918C126322002 @default.
• W2100041918 hasConceptScore W2100041918C142724271 @default.
• W2100041918 hasConceptScore W2100041918C204787440 @default.
• W2100041918 hasConceptScore W2100041918C27081682 @default.
• W2100041918 hasConceptScore W2100041918C2776136866 @default.
• W2100041918 hasConceptScore W2100041918C2776804153 @default.
• W2100041918 hasConceptScore W2100041918C2779028295 @default.
• W2100041918 hasConceptScore W2100041918C2780973058 @default.
• W2100041918 hasConceptScore W2100041918C2781212218 @default.
• W2100041918 hasConceptScore W2100041918C42219234 @default.
• W2100041918 hasConceptScore W2100041918C71924100 @default.
• W2100041918 hasConceptScore W2100041918C85663871 @default.
• W2100041918 hasConceptScore W2100041918C98274493 @default.
• W2100041918 hasIssue "4" @default.
• W2100041918 hasLocation W21000419181 @default.
• W2100041918 hasLocation W21000419182 @default.
• W2100041918 hasOpenAccess W2100041918 @default.
• W2100041918 hasPrimaryLocation W21000419181 @default.
• W2100041918 hasRelatedWork W1966894543 @default.
• W2100041918 hasRelatedWork W2055935555 @default.
• W2100041918 hasRelatedWork W2069000087 @default.
• W2100041918 hasRelatedWork W2100041918 @default.
• W2100041918 hasRelatedWork W2122960840 @default.
• W2100041918 hasRelatedWork W2983979385 @default.
• W2100041918 hasRelatedWork W3215229561 @default.
• W2100041918 hasRelatedWork W4312660866 @default.
• W2100041918 hasRelatedWork W4377862865 @default.
• W2100041918 hasRelatedWork W1994950057 @default.
• W2100041918 hasVolume "84" @default.
• W2100041918 isParatext "false" @default.
• W2100041918 isRetracted "false" @default.
• W2100041918 magId "2100041918" @default.
• W2100041918 workType "article" @default.